ATE226823T1 - Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten - Google Patents

Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Info

Publication number
ATE226823T1
ATE226823T1 AT99909110T AT99909110T ATE226823T1 AT E226823 T1 ATE226823 T1 AT E226823T1 AT 99909110 T AT99909110 T AT 99909110T AT 99909110 T AT99909110 T AT 99909110T AT E226823 T1 ATE226823 T1 AT E226823T1
Authority
AT
Austria
Prior art keywords
combination
alpha
nicotinergic
gaba
agonists
Prior art date
Application number
AT99909110T
Other languages
English (en)
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE226823T1 publication Critical patent/ATE226823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99909110T 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten ATE226823T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805559.3A GB9805559D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
PCT/GB1999/000800 WO1999047142A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist

Publications (1)

Publication Number Publication Date
ATE226823T1 true ATE226823T1 (de) 2002-11-15

Family

ID=10828630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909110T ATE226823T1 (de) 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Country Status (9)

Country Link
EP (1) EP1061925B1 (de)
JP (1) JP2002506822A (de)
AT (1) ATE226823T1 (de)
AU (1) AU752013B2 (de)
CA (1) CA2324237A1 (de)
DE (1) DE69903716T2 (de)
ES (1) ES2185321T3 (de)
GB (1) GB9805559D0 (de)
WO (1) WO1999047142A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
EP0915877A1 (de) * 1996-07-25 1999-05-19 MERCK SHARP & DOHME LTD. Substituierte triazolo-pyridazinderivate als inverse agonisten des gaba-a alpha-5 rezeptor subtyps

Also Published As

Publication number Publication date
CA2324237A1 (en) 1999-09-23
EP1061925A1 (de) 2000-12-27
JP2002506822A (ja) 2002-03-05
DE69903716T2 (de) 2003-08-14
WO1999047142A1 (en) 1999-09-23
AU752013B2 (en) 2002-09-05
DE69903716D1 (de) 2002-12-05
EP1061925B1 (de) 2002-10-30
GB9805559D0 (en) 1998-05-13
AU2847799A (en) 1999-10-11
ES2185321T3 (es) 2003-04-16

Similar Documents

Publication Publication Date Title
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
PL316658A1 (en) Novel application of serotonin antagonists
ATE346869T1 (de) Agonistische antikörper gegen tie2
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE359076T1 (de) Mittel gegen juckreiz
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE59605568D1 (de) Benzonitrile als 5-HT Agonisten und Antagonisten
BR9510499B1 (pt) antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
PT615751E (pt) Utilizacao de antagonistas de taquinina no tratamento da emese
BG105256A (en) Muscarinic agonists and antagonists
DE69918413D1 (de) Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
ATE226823T1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
NO20010509L (no) Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties